Drug Profile
Research programme: retinoic acid metabolism inhibitors - AbbVie/OPKO Health
Alternative Names: Research programme: vitamin A metabolism inhibitors - Allergan/Cytochroma; Retinoic acid metabolism inhibitors research programme - Allergan/Cytochroma; Vitamin A metabolism inhibitors research programme - Allergan/CytochromaLatest Information Update: 19 May 2020
Price :
$50
*
At a glance
- Originator Allergan; Cytochroma
- Class
- Mechanism of Action Retinoic acid metabolism modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acne; Cancer; Psoriasis
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 04 Mar 2013 Cytochroma has been acquired by OPKO Health
- 22 Jul 2004 Discontinued - Preclinical for Acne in Canada (PO)